Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.

Date publication

janvier 2024

Journal

Clinical and translational radiation oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges , Pr PEIFFERT Didier

Tous les auteurs :
Masson I, Larriviere L, Mahé MA, Azria D, Pommier P, Mesgouez-Nebout N, Giraud P, Peiffert D, Chauvet B, Dudouet P, Salem N, Noël G, Khalifa J, Latorzeff I, Guérin-Charbonnel C, Supiot S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38111609

Résumé

High-risk (HR) prostate cancer patients usually receive high-dose radiotherapy (RT) using a two-phase sequential technique, but data on a simultaneous integrated boost (SIB) technique are lacking. We prospectively evaluated the long-term results of urinary (GU) and digestive (GI) toxicity and survival data for high-dose RT using a SIB technique in HR and very high-risk (VHR) prostate cancer.

Référence

Clin Transl Radiat Oncol. 2024 01;44:100702